Shaping Evidence Strategy in an Evolving JCA Landscape
The first EU Joint Clinical Assessments (JCAs) are already reshaping market access. Here’s what manufacturers can learn from them.
Our latest paper, JCA in Practice: Early Lessons for Evidence Strategy, explores what early findings from the first JCAs mean for a manufacturer’s future evidence strategy.
What you'll learn:
- Early lessons: What the first JCAs have taught us about evidence-readiness challenges and assessment outcomes.
- What remains to be learned: How national HTA bodies may integrate JCA outputs and what this could mean for manufacturers.
- Next steps: Get to know early readiness assessments and evidence strategies to anticipate and mitigate potential access risks.
Read the paper for practical recommendations on strengthening JCA readiness, or contact our Market Access team to discuss how we can support you in navigating the evolving EU market access landscape.
The author(s)
-
Joao AtaideSenior Consultant, Market Access, UK -
Chitresh KumariPrincipal, Market Access, UK -
Andrew BallantyneHead of Market Access, UK
